Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
You're enjoying temporary access to this content

Welcome to PracticeUpdate! We hope you are enjoying temporary access to this content. Please register today for a free account and gain full access to all of our expert-selected content.

Already Have An Account? Log in Now

story of the week
Published in Oncology

Journal Scan / Research · July 25, 2023

Birtamimab Plus Standard of Care in Patients With Newly Diagnosed Treatment-Naïve Light Chain Amyloidosis

Blood

 

TAKE-HOME MESSAGE

abstract

This abstract is available on the publisher's site.

Access this abstract now  

Additional Info

Disclosure statements are available on the authors' profiles:

Blood
Birtamimab plus standard of care in light chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
Blood 2023 Jun 27;[EPub Ahead of Print], MA Gertz, AD Cohen, RL Comenzo, E Kastritis, HJ Landau, EN Libby, M Liedtke, V Sanchorawala, S Schönland, AD Wechalekar, JA Zonder, G Palladini, J Walling, S Guthrie, C Nie, C Karp, Y Jin, GG Kinney, G Merlini

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading